Prucalopride Versus Placebo in Gastroparesis

Overview

Controlled cross-over study of prucalopride 2 mg daily or placebo in gastroparesis (idiopathic or diabetic). Patients will be randomized to 4 week treatment with the first regimen (double-blind), followed by a 2-week washout and 4 week treatment with the second regimen in cross-over.

Full Title of Study: “Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 2015

Detailed Description

To assess the influence of prucalopride (Resolor®) 2mg daily, 30 patients with idiopathic and 30 patients with diabetic gastroparesis will undergo two gastric emptying breath tests with concomitant assessment of meal-related symptoms, at the conclusion of two consecutive, 4-week treatment periods of prucalopride or placebo. The order of prucalopride and placebo treatment will be randomised at the initiation of the study. Medication for both patient groups, 30 patients with idiopathic and 30 patients with diabetic gastroparesis, will be randomized separately. Half of the subjects will receive placebo first; the other half will receive prucalopride first. Treatment periods will be separated by a wash-out period of 2 weeks. All drugs potentially affecting gastrointestinal motility or sensitivity will be discontinued at least two weeks prior to the initiation of the study. Informed consent will be obtained from each participant. In order to establish the gastrointestinal symptom and quality-of-life profile of this cohort, each patient will complete the following validated self-reported instruments at baseline and at each of the two testing visits (table 1): Patients assessment of Gastrointestinal symptoms (PAGISYM), Patients assessment of Gastrointestinal Quality of Life Impact (PAGIQoL) Gastrointestinal and Global Severity Score, Patient Health Questionnaire (PHQ-15), Appetite Questionnaire, Hospital Anxiety and Depression Scale, Visceral Sensitivity Index, Short Form Nepean Dyspepsia Index (SF-NDI). The PAGI-SYM is a comprehensive questionnaire of upper GI symptoms, and it includes a gastroparesis questionnaire module: the Gastroparesis Cardinal Symptom Index (GCSI), which has been validated in (idiopathic) gastroparesis.26 Furthermore, during the entire study duration patients will complete a daily symptom diary, incorporating a separate horizontal 100-mm visual analogue scale (VAS) for each of 9 upper abdominal symptoms. As prucalopride has a well-known therapeutic effect in chronic constipation, patients will also register information about their stool frequency and stool type in the daily diary (Bristol Stool Scale).

Interventions

  • Drug: prucalopride
  • Drug: placebo

Arms, Groups and Cohorts

  • Active Comparator: Prucalopride
    • Prucalopride tablet 2 mg
  • Placebo Comparator: Placebo
    • matching placebo tablet

Clinical Trial Outcome Measures

Primary Measures

  • GCSI questionnaire score
    • Time Frame: after 4 weeks
    • validated gastroparesis questionnaire

Secondary Measures

  • PAGI SYM questionnaire scores
    • Time Frame: after 4 weeks
    • validated upper GI questionnaire
  • NDI questionnaire scores
    • Time Frame: after 4 weeks
    • validated upper GI QOL questionnaire
  • Gastric half emptying time
    • Time Frame: after 4 weeks
    • gastric emptying test
  • Daily diary symptom and stool pattern scores
    • Time Frame: over 4 weeks, weekly average
    • daily symptom diaries

Participating in This Clinical Trial

Inclusion Criteria

  • Consecutive patients with a previously established diagnosis of diabetes or functional dyspepsia according to Rome III criteria, and with delayed gastric emptying (t1/2 for solids ≥ 109 min) on a breath test Exclusion Criteria:

  • The presence of oesophagitis, gastric atrophy or erosive gastroduodenal lesions on endoscopy – the presence of lesions on small bowel X-ray – major abdominal surgery – underlying psychiatric illness – use of non-steroidal anti-inflammatory drugs, steroids, or drugs affecting gastric motility. – Major co-morbidities

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Universitaire Ziekenhuizen KU Leuven
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Jan Tack, M.D., Ph.D., +3216344228, jan.tack@med.kuleuven.be

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.